Meeting
2023 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel versus bacillus Calmette-Guérin for the treatment of high-risk, treatment-naïve, non-muscle invasive bladder cancer.
Authors
Ian M. McElree
The University of Iowa Carver College of Medicine, Iowa City, IA
Ian M. McElree , Ryan L. Steinberg , Sarah L. Mott , Michael A. O'Donnell , Vignesh T. Packiam
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 497)
DOI
10.1200/JCO.2023.41.6_suppl.497
Abstract #
497
Poster Bd #
K1
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2024 ASCO Genitourinary Cancers Symposium
Population based trends in intravesical gemcitabine use among patients with high-risk non-muscle invasive bladder cancer.
First Author: Stephen B. Williams
Poster
2024 ASCO Genitourinary Cancers Symposium
Cost-effectiveness-analysis of different treatment modalities in bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NIMBC).
First Author: Constantin Rieger
Poster
2024 ASCO Genitourinary Cancers Symposium
Reasons for refusal of or ineligibility for radical cystectomy (RC) in patients (Pts) with bacillus Calmette-Guérin (BCG)–unresponsive high-risk non–muscle-invasive bladder cancer (HR NMIBC) from the SunRISe-1 study.
First Author: Joseph M Jacob